Canadian Medical Association Journal, Vol 149, Issue 10 1401-1407, Copyright © 1993 by Canadian Medical Association

JOURNAL ARTICLE

Interactions between physicians and the pharmaceutical industry: what does the literature say?

J. Lexchin
Emergency Department, Toronto Hospital, Ont.

OBJECTIVE: To determine the effect of three types of interaction between physicians and the pharmaceutical industry--company-funded clinical trials, company-sponsored continuing medical education (CME) and information for physicians supplied by pharmaceutical detailers--on orientation and quality of clinical trials, content of CME courses and physicians' prescribing behaviour. DATA SOURCES: MEDLINE and HEALTH searches for English-language articles published from 1978 to 1993, supplemented by material from the author's personal collection. STUDY SELECTION: A total of 227 papers from the MEDLINE and HEALTH searches and about 2000 items from the author's library were initially reviewed. The following selection criteria were used: studies conducted in Australia, Canada, New Zealand, Britain and the United States; studies conducted after 1977; quantitative surveys containing details of the survey methods; studies on the orientation and quality of company-funded clinical trials and on the content of CME courses giving explicit criteria used in the evaluation; and reports on the outcome of interactions stating how the outcomes were assessed. Thirty-six studies met these criteria. DATA EXTRACTION: Information was extracted on five topics: physicians' attitudes toward drug industry interactions, frequency with which physicians participate in the interactions, orientation and quality of company-funded clinical trials, content of company-sponsored CME courses and changes in physicians' prescribing behaviour as a result of an interaction. DATA SYNTHESIS: Although most physicians participate only occasionally in company-sponsored clinical trials, most see detailers and attend company-sponsored CME courses. However, physicians do not have a very high opinion of the information from detailers or of company-sponsored CME events. Many doctors regard pharmaceutical companies as an important source of funding for clinical trials, but they also have concerns about accepting money from this source. Company funding of clinical trials may affect the quality of the trials and the types of research that physicians undertake. Company-sponsored CME courses may have a commercial bias even if conducted under guidelines designed to ensure the independence of the event. All three types of interactions affect physicians' prescribing behaviour and, in the case of obtaining information from detailers, physicians' prescribing practices are less appropriate as a result of the interaction. CONCLUSIONS: Physicians are affected by their interactions with the pharmaceutical industry. Further research needs to be done in most cases to determine whether such interactions lead to more or less appropriate prescribing practices. The CMA's guidelines on this topic should be evaluated to see whether they are effective in controlling physician-industry interactions. Further measures may be necessary if the guidelines fail to prevent negative effects on prescribing practices.

This article has been cited by other articles:

				G. Thanassoulis, I. Karp, K. Humphries, J. V. Tu, M. J. Eisenberg, and L. Pilote Impact of Restrictive Prescription Plans on Heart Failure Medication Use Circ Cardiovasc Qual Outcomes, September 1, 2009; 2(5): 484 - 490. [Abstract] [Full Text] [PDF]

				A. Pisacane Rethinking continuing medical education BMJ, August 14, 2008; 337(aug14_1): a973 - a973. [Full Text]

				L. M. Furman Attention-Deficit Hyperactivity Disorder (ADHD): Does New Research Support Old Concepts? J Child Neurol, July 1, 2008; 23(7): 775 - 784. [Abstract] [PDF]

				M. Civaner, O. Sarikaya, S. U. Alici, and G. Bozkurt Exposing Nursing Students To the Marketing Methods of Pharmaceutical Companies Nursing Ethics, May 1, 2008; 15(3): 396 - 410. [Abstract] [PDF]

				J. Kreyenbuhl, S. C. Marcus, J. C. West, J. Wilk, and M. Olfson Adding or Switching Antipsychotic Medications in Treatment-Refractory Schizophrenia Focus, April 1, 2008; 6(2): 212 - 220. [Abstract] [Full Text] [PDF]

				R. Moynihan Doctors' education: the invisible influence of drug company sponsorship BMJ, February 23, 2008; 336(7641): 416 - 417. [Full Text] [PDF]

				N. Pearce Corporate influences on epidemiology Int. J. Epidemiol., February 1, 2008; 37(1): 46 - 53. [Abstract] [Full Text] [PDF]

				A. E. Carroll, R. C. Vreeman, J. Buddenbaum, and T. S. Inui To What Extent Do Educational Interventions Impact Medical Trainees' Attitudes and Behaviors Regarding Industry-Trainee and Industry-Physician Relationships? Pediatrics, December 1, 2007; 120(6): e1528 - e1535. [Abstract] [Full Text] [PDF]

				M. E. Fallat, J. Glover, and the Committee on Bioethics Professionalism in Pediatrics Pediatrics, October 1, 2007; 120(4): e1123 - e1133. [Abstract] [Full Text] [PDF]

				M. D. Jibson Interactions Between Physicians and Industry: A Guide for Clinicians Focus, January 1, 2007; 5(4): 398 - 406. [Abstract] [Full Text] [PDF]

				M. E. Gozum Academic medical centers and conflicts of interest. JAMA, June 28, 2006; 295(24): 2845 - 2845. [Full Text] [PDF]

				C. A. Vassilas and S. Matthews Pharmaceutical sponsorship of educational events: what can we learn from healthcare ethics? Psychiatr. Bull., May 1, 2006; 30(5): 189 - 191. [Full Text] [PDF]

				P. S. Mueller, C. M. Segovis, S. C. Litin, T. M. Habermann, and T. A. Parrino Current Status of Medical Grand Rounds in Departments of Medicine at US Medical Schools Mayo Clin. Proc., March 1, 2006; 81(3): 313 - 321. [Abstract] [Full Text] [PDF]

				M. L. Randall, J. R. Rosenbaum, R. M. Rohrbaugh, and R. A. Rosenheck Attitudes and Behaviors of Psychiatry Residents Toward Pharmaceutical Representatives Before and After an Educational Intervention Acad Psychiatry, March 1, 2005; 29(1): 33 - 39. [Abstract] [Full Text] [PDF]

				S. B. Leichter Continuing Medical Education in Diabetes: The Impending Crisis Clin. Diabetes, October 1, 2004; 22(4): 174 - 177. [Full Text] [PDF]

				D. A. Davis CME and the pharmaceutical industry: two worlds, three views, four steps Can. Med. Assoc. J., July 20, 2004; 171(2): 149 - 150. [Full Text] [PDF]

				M. R. Patel, T. J. Meine, J. Radeva, L. Curtis, S. V. Rao, K. A. Schulman, and J. G. Jollis State-mandated continuing medical education and the use of proven therapies in patients with an acute myocardial infarction J. Am. Coll. Cardiol., July 7, 2004; 44(1): 192 - 198. [Abstract] [Full Text] [PDF]

				J. A. Greene Attention to 'Details':: Etiquette and the Pharmaceutical Salesman in Postwar American Social Studies of Science, April 1, 2004; 34(2): 271 - 292. [Abstract] [PDF]

				G. T Schumock, S. M Walton, H. Y Park, E. A Nutescu, J. C Blackburn, J. M Finley, and R. K Lewis Factors that Influence Prescribing Decisions Ann. Pharmacother., April 1, 2004; 38(4): 557 - 562. [Abstract] [Full Text] [PDF]

				J. Dana and G. Loewenstein A Social Science Perspective on Gifts to Physicians From Industry JAMA, July 9, 2003; 290(2): 252 - 255. [Full Text] [PDF]

				R. Moynihan Who pays for the pizza? Redefining the relationships between doctors and drug companies. 1: Entanglement BMJ, May 29, 2003; 326(7400): 1189 - 1192. [Full Text] [PDF]

				A. C. Tsai Concern About Drug Reps Health Aff., July 1, 2002; 21(4): 296 - 297. [Full Text] [PDF]

				J.E.F. Zwart-van Rijkom, F.J. Broekmans, and H.G.M. Leufkens From HMG through purified urinary FSH preparations to recombinant FSH: a substitution study Hum. Reprod., April 1, 2002; 17(4): 857 - 865. [Abstract] [Full Text] [PDF]

				S. L. Coyle and for the Ethics and Human Rights Committee, America Physician-Industry Relations. Part 1: Individual Physicians Ann Intern Med, March 5, 2002; 136(5): 396 - 402. [Abstract] [Full Text] [PDF]

				B. B. McCormick, G. Tomlinson, P. Brill-Edwards, and A. S. Detsky Effect of Restricting Contact Between Pharmaceutical Company Representatives and Internal Medicine Residents on Posttraining Attitudes and Behavior JAMA, October 24, 2001; 286(16): 1994 - 1999. [Abstract] [Full Text] [PDF]

				D. Cohen, M. McCubbin, J. Collin, and G. Perodeau Medications as Social Phenomena Health (London) , October 1, 2001; 5(4): 441 - 469. [Abstract] [PDF]

				M. E. Dieperink and L. Drogemuller Industry-Sponsored Grand Rounds and Prescribing Behavior JAMA, March 21, 2001; 285(11): 1443 - 1444. [Full Text] [PDF]

				A. Wazana Physicians and the Pharmaceutical Industry: Is a Gift Ever Just a Gift? JAMA, January 19, 2000; 283(3): 373 - 380. [Abstract] [Full Text] [PDF]

				D. Griffith Reasons for not seeing drug representatives BMJ, July 10, 1999; 319(7202): 69 - 70. [Full Text]

				J. M. Westfall, J. McCabe, and R. A. Nicholas Personal Use of Drug Samples by Physicians and Office Staff JAMA, July 9, 1997; 278(2): 141 - 143. [Abstract] [PDF]

				D. E. Barnes and L. A. Bero Industry-Funded Research and Conflict of Interest: An Analysis of Research Sponsored by the Tobacco Industry through the Center for Indoor Air Research Journal of Health Politics Policy and Law, September 1, 1996; 21(3): 515 - 542. [Abstract] [PDF]

				A. G. Mainous III, W. J. Hueston, and E. C. Rich Patient Perceptions of Physician Acceptance of Gifts From the Pharmaceutical Industry Arch Fam Med, April 1, 1995; 4(4): 335 - 339. [Abstract] [PDF]

HOME	CURRENT ISSUE	PAST ISSUES	COLLECTIONS	HELP	SEARCH
Copyright 1995-1993, Canadian Medical Association. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p) All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association.